HALO - Halozyme Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
181,885
151,862
316,613
146,691
135,057
Cost of Revenue
12,774
10,136
31,152
33,206
29,245
Gross Profit
169,111
141,726
285,461
113,485
105,812
Operating Expenses
Research Development
137,428
150,252
150,643
150,842
93,236
Selling General and Administrative
68,239
60,804
53,816
45,853
40,028
Total Operating Expenses
205,667
211,056
204,459
196,695
133,264
Operating Income or Loss
-36,556
-69,330
81,002
-83,210
-27,452
Interest Expense
13,859
18,041
21,984
19,977
5,201
Total Other Income/Expenses Net
7,967
7,578
2,592
1,326
422
Income Before Tax
-42,448
-79,793
61,610
-101,861
-32,231
Income Tax Expense
356
537
-1,361
1,162
-
Income from Continuing Operations
-42,804
-80,330
62,971
-103,023
-32,231
Net Income
-42,804
-80,330
62,971
-103,023
-32,231
Net Income available to common shareholders
-42,804
-80,330
62,971
-103,023
-32,231
Reported EPS
Basic
-
-0.56
0.46
-0.81
-0.25
Diluted
-
-0.56
0.45
-0.81
-0.25
Weighted average shares outstanding
Basic
-
143,599
136,419
127,964
126,704
Diluted
-
143,599
139,068
127,964
126,704
EBITDA
-
-61,752
83,594
-81,884
-27,030